Skip to main content
Cloudbreak Pharma Inc. logo

Cloudbreak Pharma Inc. — Investor Relations & Filings

Ticker · 2592 HKEX Manufacturing
Open in API
Filings indexed 71 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2592

About Cloudbreak Pharma Inc.

https://cloudbreakpharma.com/

Cloudbreak Pharma Inc. is an innovative, clinical-stage ophthalmology biotechnology company dedicated to the research and development of novel and differentiated treatments for chronic eye diseases. The company focuses on improving vision quality globally by developing therapies for both anterior and posterior segment ophthalmic conditions. Its robust pipeline includes products targeting pterygium, pinguecula, meibomian gland dysfunction, glaucoma filtration surgery, age-related macular degeneration, and diabetic retinopathy. Cloudbreak utilizes advanced platforms, including a potent multi-kinase inhibitor formulated as a topical eye drop for anterior segment diseases and a unique Antibody-Drug Synergism Platform for posterior segment diseases.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY SINGLE LARGEST SHAREHOLDER
Regulatory Filings Classification · 1% confidence The document is a 'Voluntary Announcement' issued by Cloudbreak Pharma Inc. regarding the voluntary extension of a lock-up period by a single largest shareholder. It does not fit into specific categories like financial reports, dividends, or director dealings. Since it is a regulatory announcement regarding corporate capital structure and shareholder commitments that does not fall into the other specific categories, it is best classified as a general regulatory filing.
2025-12-29 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE IN RELATION TO SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Cloudbreak Pharma Inc. regarding the submission of an Investigational New Drug (IND) application to the FDA for a drug candidate (CBT-199). It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a general corporate update regarding business development and regulatory progress that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2025-12-15 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE IN RELATION TO SUCCESSFUL END-OF-PHASE 2 MEETING
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Cloudbreak Pharma Inc. regarding the successful outcome of an End-of-Phase 2 meeting with the FDA for a drug candidate (CBT-004). It does not fit into specific categories like financial reports, dividend notices, or director dealings. As it is a general corporate update regarding business operations and regulatory progress that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2025-12-12 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE
Regulatory Filings Classification · 1% confidence The document is a 'Voluntary Announcement' issued by Cloudbreak Pharma Inc. regarding a business update concerning an upcoming FDA meeting for a clinical-stage drug candidate (CBT-004). It does not fit into specific categories like financial reports, dividend notices, or director dealings. As it is a general regulatory announcement regarding business operations that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2025-12-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not represent a specific corporate event like a dividend announcement or a major shareholding change, but rather a routine regulatory disclosure of share capital status. Therefore, it falls under the 'Regulatory Filings' category.
2025-12-01 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE IN RELATION TO SUCCESSFUL PATENT APPLICATIONS IN JAPAN AND EUROPE
Regulatory Filings Classification · 1% confidence The document is a 'Voluntary Announcement' issued by Cloudbreak Pharma Inc. regarding the successful grant of patents in Japan and Europe for their core product, CBT-009. It provides business updates, context on the product's development, and future commercialization strategy. It does not fit into specific categories like financial reports, dividend notices, or director dealings. As it is a general corporate announcement regarding business operations that does not fall into a more specific category, it is classified as a Regulatory Filing (RNS).
2025-11-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.